The US Biotechnology Market Future Outlook to 2016.pdf
《The US Biotechnology Market Future Outlook to 2016.pdf》由会员分享,可在线阅读,更多相关《The US Biotechnology Market Future Outlook to 2016.pdf(111页珍藏版)》请在三一文库上搜索。
1、1 This is a licensed product of Ken Research and should not be copied 2 This is a licensed product of Ken Research and should not be copied TABLE OF CONTENTS List of Figures .6 List of Tables 8 1. The US Biotechnology Market Introduction .9 2. The US Biotechnology Market Size by Revenue, 2006-2011 .
2、 11 3. The US Biotechnology Market Segmentation By Application, 2006-2011 13 3.1. The US Bio-Pharmaceutical/Biologics Market Size and Introduction, 2006-2011 15 3.1.1. Top Selling Biologic Drugs, 2010 16 3.1.2. The US Bio-Pharmaceuticals Market Trends And Developments . 17 Bio-Pharmaceutical Compani
3、es Focus on Outsourcing as Short Term Strategy . 17 High Approvals Increasing the Number of Bio-Pharmaceutical Products 18 3.1.3. Top US Biopharmaceutical Companies Market Share, 2011. 19 3.1.4. Biologic Drugs Future Projections, 2012-2016 . 21 3.1.5. Major Bio-Pharmaceutical Company Profiles. 22 3.
4、1.5.1. Pfizer Inc. . 22 Company Overview 22 Business Strategies 23 Financial Performance 24 3.1.5.2. Merck the Animal and Plant Health Inspection Service (APHIS) which controls bio-agriculture; and the Environmental Protection Agency (EPA) regulates bio-industrials associated with the energy and the
5、 environment. These agencies work with the objective of maintaining a balance between the benefits of the biotechnology products and services and their potential threat to the public and the environment. Besides this, the US government plays a key role in setting stage for the growth of the biotechn
6、ology industry by protecting intellectual capital, funding the various R agricultural and aquacultural technologies; industrial technologies; 73,205.3 89,760.8 1,08,430.9 1,16,366.8 1,28,454.7 1,35,339.1 0.0 20,000.0 40,000.0 60,000.0 80,000.0 1,00,000.0 1,20,000.0 1,40,000.0 1,60,000.0 200620072008
7、200920102011 USD Millions 14 This is a licensed product of Ken Research and should not be copied animal health, marine and terrestrial technologies; and, environmental remediation and natural resources recovery. The revenues generated from product sales, licensing fees, royalties and research fundin
8、g for companies reflect the market value of a segment. The human health technologies have accounted for 57% of the US biotechnology products and services market and represents the largest share. The agriculture and aquaculture technologies accounts for 15% share while the industrial technologies mak
9、e up 12% of the market share. In addition to this, the animal health, marine and terrestrial technologies as well as environmental remediation and natural resources recovery segments represents 8% of the US biotechnology market. The US biotechnology market can be classified into three segments- Bio-
10、Pharma, Industrial biotechnology and Agricultural biotechnology. The bio-pharma represents the largest segment in the US biotechnology market. This is followed by industrial biotechnology which is the second largest contributor in the US biotechnology market. The agricultural biotechnology is on thi
11、rd place and contributes relatively less to the US biotechnology market. The contribution of bio- pharma has declined from 62.2% in 2006 to 48.7% in 2011 in the overall US biotechnology market. For industrial biotechnology the contribution in the US biotechnology market has increased from 32.8% in 2
12、006 to 47.0% in 2011 and the contribution of agricultural biotechnology reached 4.3% in 2011 fell by 0.7 % from 5.0% in 2006. Figure 2: The US Biotechnology Market Segmentation by Bio-Pharmaceuticals,Agriculture Biotech and Industrial Biotechnology in Percentage, 2006-2011 Source: Ken Research 62.2%
13、 55.5% 49.1%49.7% 47.7% 48.7% 32.8% 40.0% 46.7%46.0% 48.1%47.0% 5.0%4.5%4.3%4.3%4.1%4.3% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0% 100.0% 200620072008200920102011 In Percentage (%) Bio PharmaIndustrial BiotechnologyAgriculture Biotech 15 This is a licensed product of Ken Research an
14、d should not be copied 3.1. THE US BIO-PHARMACEUTICAL/BIOLOGICS MARKET SIZE AND INTRODUCTION, 2006-2011 Biologic drugs are gradually increasing their share over the period. These protein based drugs, mainly produced using Recombinant DNA technology, and are used increasingly to treat numerous condit
15、ions. Biological drugs are generally more expensive than the conventional drugs thus acting as a key revenue earners for producers. The top categories of biologic drugs in terms of sales are monoclonal antibodies (mABS) and Hormones and Growth factors. Stem cell research is going forward at a rapid
16、pace. The Obama administration has relaxed the restrictions on federal funding of stem cell research that were instituted by the foregoing administration. In 2009, the National Institutes of Health (NIH) had laid down new guidelines for funding which will increase the number of stem cell lines that
17、qualify for research funds from a preceding 21 to as many as 700. Nonetheless, research of certain extremely controversial stem cells, for instance those developed through cloning, will not be funded with federal dollars. In spite of the significant advancements in biopharmaceutical knowledge and te
18、chnology, the biopharmaceutical companies continue to confront hardships in the form of long timeframes, high costs and massive risks in developing, commercializing and launching a new product into the market. The number of drugs getting approved is relatively less as compared to the total number of
19、 drugs developed. Out of those approved drugs, few make it to the clinical trials, and even fewer are launched. Of those launched, only a small number of drugs generate revenues to recover their costs and they are also daunted by the shortening patent period. Once the market exclusivity and patent e
20、xtension ceases, the market share of these innovator biologics are hastily eaten up by their generic counterparts. The total US biologic drugs market grew from USD 45.5 billion in 2006 to USD 65.9 billion in 2011 at a 5 year CAGR of 7.7%. The total US biologic drugs market grew from USD 45.5 billion
21、 in 2006 to USD 65.9 billion in 2011 at a 5 year CAGR of 7.7%. 16 This is a licensed product of Ken Research and should not be copied Figure 3: The US Biopharmaceuticals Market Size by Revenue in USD Billion, 2006-2011 Source: Ken Research 3.1.1. TOP SELLING BIOLOGIC DRUGS, 2010 Avastin, Rituxan, En
22、brel and Remicade are among the worlds top selling biologics and each recorded sales above USD 3.0 billion in the US in 2010. Avastin (Bevacizumab) by Genentech/Roche was among the top selling drugs worldwide in 2010. This drug is prescribed for treating brain tumor and certain types of cancer of th
23、e colon, rectum, lungs and kidney. In 2010, Avastin recorded sales of USD 4.0 billion in the US. Rituxan is also a major biologic marketed by Roche. Rituxan is a monoclonal antibody prescribed for the treatment of non-Hodgkins lymphoma (NHL) This drug registered sales of USD 3.8 billion in 2010. Enb
24、rel (Etanercept) is a TNF (Tumor Necrosis Factor) inhibitor used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Enbrel generated sales of USD 3.3 billion in 2010. Remicade (Infliximab) is a monoclonal antibody against tumour necrosis factor alpha (TNF) used for the treatment o
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- The US Biotechnology Market Future Outlook to 2016
链接地址:https://www.31doc.com/p-3800949.html